Trusted Resources: Education
Scientific literature and patient education texts
Activity of Daily Living in Mucopolysaccharidosis IVA patients: Evaluation of Therapeutic Efficacy
source: Molecular genetics & genomic medicine
year: 2021
authors: Chen H,Khan S,Celik B,Suzuki Y,Ago Y,Tomatsu S
summary/abstract:Mucopolysaccharidosis IVA (MPS IVA, also called Morquio A syndrome) is caused by a deficiency of N-acetylglucosamine-6-sulfate sulfatase (GALNS) and results in skeletal dysplasia symptoms such as short stature and abnormal gait. Treatments include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), but the effects are limited depending on the age of initiation and clinical phenotype. Thus, this study aims to assess the effects of treatments on MPS IVA patients compared to untreated MPS IVA patients and an age-matched control group.
organization: University of Delaware, Newark, DE, USA.DOI: 10.1002/mgg3.1806
read more
Related Content
-
Oliver’s Tomorrow Night at Columbus Blue JacketsThe NHL’s Columbus Blue Jackets are de...
-
Aiden and Aj’s Story – Living With Hunter Syndromehttps://www.youtube.com/watch?v=9rt-e3Ky...
-
Fatal Care Research FoundationFatal Care Research Center inaugurated a...
-
National MPS Society – FacebookNational MPS Society is a nonprofit orga...
-
Clinical Features and Health-Related Quality of Life in Adult Patients With Mucopolysaccharidosis IVA: The Spanish E...Mucopolysaccharidosis (MPS) IVA or Morqu...
-
Believe in G Golf TournamentGianna, was diagnosed with Sanfilippo Sy...
-
Cure Sanfilippo FoundationCure Sanfilippo Foundation is a Not-for-...